Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

Media Library

Dr Hope Rugo discusses studies that are aiming to evaluate the effect that CDK4/6 inhibitors have on patients with HER2+ breast cancer.
Hope S. Rugo, MD, describes how she would treat a patient with HER-positive metastatic breast cancer that has progressed with a CDK4/CDK6 inhibitor plus an aromatase inhibitor.
Dr Hope Rugo addresses some of the main differences between the 3 CDK4/6 inhibitors that are FDA-approved in HR-positive metastatic breast cancer.
Dr Hope Rugo cites that CDK4/6 inhibitors play a critical role in estrogen signaling and can be very effective in treating metastatic breast cancer when used in combination with hormone therapy.
The WCGIC chairperson, professor Eric Van Cutsem, MD, PhD, heads the Division of Digestive Oncology at University Hospitals Leuven and KU Leuven, Leuven, Belgium. He describes the difference between left- and right-sided colon cancers in terms of prognosis and response to therapy.
Dr. Valérie Vilgrain discusses SIRT Y-90 and the results of the SARAH trial.
Eric Allan, MD, discusses the clinical significance of his research and case study, “Low-Level Laser Therapy Reduces Pain in Patients with Head and Neck Cancer.”
Carryn Anderson, MD, discusses the clinical significance of her research on, “Severe Oral Mucositis Less Frequent, Briefer, Less Severe with Use of GC4419.”
Jennifer Brown, MD, PhD, expanded upon the results of her and her colleagues’ study of the hepatotoxic effects of idelalisib, particularly as frontline treatment of younger patients with chronic lymphocytic leukemia, which was presented at the 57th American Society of Hematology Annual Meeting & Exposition.
William A. Zellmer, BPharm, MPH, discusses how the 4th edition of the American Society of Health-System Pharmacists (ASHP) Foundation’s Pharmacy Forecast serves to improve the effectiveness of leaders in hospital and health-system pharmacy practice.
Page 5 of 6
Results 41 - 50 of 54